Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11396992 | 0.85 | RAB9A (0.61) | RAB9AKDM4ENPC1HCAR3SMN1; SMN2 | |
| SCHEMBL18250728 | 0.83 | NPC1 (0.43) | RAB9AKDM4ENPC1HCAR3SMN1; SMN2 | |
| SCHEMBL6175527 | 0.82 | BRD4 (0.41) | RAB9AKDM4ENPC1HCAR3SMN1; SMN2 | |
| SCHEMBL22272322 | 0.81 | HCAR3 (0.47) | RAB9AKDM4ENPC1HCAR3SMN1; SMN2 | |
| SCHEMBL18250729 | 0.81 | TNF (0.39) | RAB9AKDM4ENPC1SMN1; SMN2HPGD | |
| SCHEMBL18250698 | 0.80 | BRD4 (0.40) | RAB9AKDM4ENPC1SMN1; SMN2HPGD | |
| SCHEMBL23063551 | 0.80 | HCAR3 (0.50) | RAB9AKDM4ENPC1HCAR3SMN1; SMN2 | |
| SCHEMBL7726920 | 0.80 | HCAR3 (0.46) | RAB9AKDM4ENPC1HCAR3SMN1; SMN2 | |
| SCHEMBL15723611 | 0.80 | HCAR3 (0.46) | RAB9AKDM4ENPC1HCAR3SMN1; SMN2 | |
| SCHEMBL19836338 | 0.80 | GLP1R (0.53) | RAB9AKDM4ENPC1HCAR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2023-12-14 | — | — | US | disclosed |
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9499529-B2 | Therapeutic uses of curcumin analogs for treatment of prostate cancer | CALIFORNIA STATE UNIVERSITY, FRESNO (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2016-11-10 | — | — | US | disclosed |
| WO-2016164641-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20130005739-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING A COS RELEASING COMPOUND | LUDWIG BOLTZMANN CLUSTER FUER KARDIOVASKULAERE FORSCHUNG (AT) | 2013-01-03 | — | — | US | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358936-B2 | Lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | RAB9A 4612/4885KDM4E 1498/4885NPC1 1843/4885 |
| US-20210171465-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | RAB9A 4612/4885KDM4E 1498/4885NPC1 1843/4885 |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | RAB9A 3611/4885KDM4E 2256/4885NPC1 2529/4885 |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | LCK, WEE1, JAK1 | RAB9A 1708/4885KDM4E 2096/4885NPC1 3516/4885 |
| US-20130005739-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING A COS RELEASING COMPOUND | VIP, CRH, ADCYAP1R1 | RAB9A 430/4885KDM4E 4765/4885NPC1 55/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | RAB9A 3611/4885KDM4E 2256/4885NPC1 2529/4885 |
| US-20160326162-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP4K2, PLK1 | RAB9A 1950/4885KDM4E 2226/4885NPC1 2140/4885 |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | LCK, WEE1, JAK1 | RAB9A 1708/4885KDM4E 2096/4885NPC1 3516/4885 |
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CAT, MPO, NISCH | RAB9A 1341/4885KDM4E 4759/4885NPC1 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.